Share this article

Swiss-based biopharmaceutical company Neurimmune has reported a positive outcome from its Phase Ib PRIME clinical trial of aducanumab to treat early stage Alzheimer's disease (AD).

Aducanumab has been developed in association with Biogen and is based on Neurimmune's patented Reverse Translational Medicine (RTM) technology platform.

It is developed as a human-recombinant monoclonal antibody derived from a de-identified library of B-cells and collected from healthy elderly subjects displaying no signs of cognitive impairment or cognitively impaired elderly people with unusually slow cognitive decline.

Aducanumab targets aggregated forms of beta amyloid, namely soluble oligomers and insoluble fibrils deposited into the amyloid plaque within the brain of patients with Alzheimer's disease.

Results of the study demonstrated the efficacy of aducanumab in removing amyloid plaques from the brains of patients suffering from early stage AD.

After the administration of aducanumab to the patients for one year, positron emission tomography (PET) displayed reduced levels of amyloid plaques.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Further evidence validated the efficacy of aducanumab in slowing the cognitive decline within patients.

"These results potentially represent a major step forward in the fight against Alzheimer's disease, and the magnitudes of the effects."

Neurimmune co-founder and president Roger Nitsch said: "These results potentially represent a major step forward in the fight against Alzheimer's disease, and the magnitudes of the effects, as well as their time-dependency and dose-dependency are truly intriguing.

"Aducanumab also demonstrates a proof-of-concept for our RTM technology platform. It gives us further evidence that our approach is working and provides promise for many of the other drugs we are developing using this technology."

Findings of the study also included safety related, transient, amyloid-related imaging abnormalities (ARIA).

The company is also conducting Phase III clinical trials named ENGAGE and EMERGE of aducanumab, to further validate the safety and efficacy of the drug in treating approximately 2,700 people with early Alzheimer's disease.

Image: Neurimmune study results shows improvement in Alzheimer's disease. Photo: courtesy of PRNewsFoto/Neurimmune.